bioAffinity Technologies Presents Veteran-Focused Lung Cancer Data at NAVREF 2026
Event summary
- bioAffinity Technologies will present two posters on CyPath® Lung at the NAVREF 2026 Annual Conference, September 27-30, 2026.
- Posters highlight clinical cases and ongoing research in veteran and military populations.
- CyPath Lung demonstrated 92% sensitivity, 87% specificity, and 99% negative predictive value in detecting early-stage lung cancer.
- The FlowPath™ Lung study is enrolling 2,000 patients across 12 VA medical centers and two military hospitals.
The big picture
bioAffinity Technologies is positioning CyPath Lung as a key diagnostic tool for early lung cancer detection, particularly in high-risk veteran populations. The company's focus on noninvasive, AI-driven diagnostics aligns with broader industry trends toward personalized and preventive healthcare. The partnership with AvMEDICAL signals a strategic push into the federal healthcare market, where the VA's expanded lung cancer screening programs present a significant growth opportunity.
What we're watching
- Clinical Validation
- Whether CyPath Lung's performance metrics in veteran populations will translate to broader clinical settings.
- Commercial Momentum
- The pace at which bioAffinity Technologies can scale its partnership with AvMEDICAL to expand market reach.
- Regulatory Dynamics
- How changes in healthcare reimbursement policies may impact the adoption of CyPath Lung.
Related topics